Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2-Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan.

Amano, Masayuki; Maeda, Kenji; Tsuchiya, Kiyoto; Shimada, Shinya; Mitsuya, Hiroaki

Amano, Masayuki; Maeda, Kenji; Tsuchiya, Kiyoto; Shimada, Shinya; Mitsuya, Hiroaki.

Afiliación

Amano M; Department of Hematology, Rheumatology, and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan.
Maeda K; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Tsuchiya K; AIDS Clinical Center, National Center for Global Health and Medicine Hospital, Tokyo, Japan.
Shimada S; Japan Community Health care Organization (JCHO) Kumamoto General Hospital, Kumamoto, Japan.
Mitsuya H; Department of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.

J Infect Dis ; 226(11): 2038-2039, 2022 11 28.

Article en En | MEDLINE | ID: mdl-35580786

Asunto(s)

Vacuna BNT162; COVID-19; Humanos; Japón; SARS-CoV-2; COVID-19/prevención & control; Anticuerpos Neutralizantes; Anticuerpos Antivirales; Vacunación

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: COVID-19 / Vacuna BNT162 Límite: Humans País/Región como asunto: Asia Idioma: En Revista: J Infect Dis Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google